Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 108

1.
2.

A highly infectious Plasmodium yoelii parasite, bearing Plasmodium falciparum circumsporozoite protein.

Zhang M, Kaneko I, Tsao T, Mitchell R, Nardin EH, Iwanaga S, Yuda M, Tsuji M.

Malar J. 2016 Apr 12;15:201. doi: 10.1186/s12936-016-1248-z.

3.

Human immune system mice immunized with Plasmodium falciparum circumsporozoite protein induce protective human humoral immunity against malaria.

Huang J, Li X, Coelho-dos-Reis JG, Zhang M, Mitchell R, Nogueira RT, Tsao T, Noe AR, Ayala R, Sahi V, Gutierrez GM, Nussenzweig V, Wilson JM, Nardin EH, Nussenzweig RS, Tsuji M.

J Immunol Methods. 2015 Dec;427:42-50. doi: 10.1016/j.jim.2015.09.005. Epub 2015 Sep 26.

PMID:
26410104
4.

Human-induced nitrogen-phosphorus imbalances alter natural and managed ecosystems across the globe.

Peñuelas J, Poulter B, Sardans J, Ciais P, van der Velde M, Bopp L, Boucher O, Godderis Y, Hinsinger P, Llusia J, Nardin E, Vicca S, Obersteiner M, Janssens IA.

Nat Commun. 2013;4:2934. doi: 10.1038/ncomms3934.

PMID:
24343268
5.

Protective humoral immunity elicited by a needle-free malaria vaccine comprised of a chimeric Plasmodium falciparum circumsporozoite protein and a Toll-like receptor 5 agonist, flagellin.

Carapau D, Mitchell R, Nacer A, Shaw A, Othoro C, Frevert U, Nardin E.

Infect Immun. 2013 Dec;81(12):4350-62. doi: 10.1128/IAI.00263-13. Epub 2013 Sep 16.

6.

Imaging murine NALT following intranasal immunization with flagellin-modified circumsporozoite protein malaria vaccines.

Nacer A, Carapau D, Mitchell R, Meltzer A, Shaw A, Frevert U, Nardin EH.

Mucosal Immunol. 2014 Mar;7(2):304-14. doi: 10.1038/mi.2013.48. Epub 2013 Jul 3.

7.

Plasmodium falciparum synthetic LbL microparticle vaccine elicits protective neutralizing antibody and parasite-specific cellular immune responses.

Powell TJ, Tang J, Derome ME, Mitchell RA, Jacobs A, Deng Y, Palath N, Cardenas E, Boyd JG, Nardin E.

Vaccine. 2013 Apr 8;31(15):1898-904. doi: 10.1016/j.vaccine.2013.02.027. Epub 2013 Feb 26.

8.

Sporozoite neutralizing antibodies elicited in mice and rhesus macaques immunized with a Plasmodium falciparum repeat peptide conjugated to meningococcal outer membrane protein complex.

Przysiecki C, Lucas B, Mitchell R, Carapau D, Wen Z, Xu H, Wang XM, Nahas D, Wu C, Hepler R, Ottinger E, Ter Meulen J, Kaslow D, Shiver J, Nardin E.

Front Cell Infect Microbiol. 2012 Nov 30;2:146. doi: 10.3389/fcimb.2012.00146. eCollection 2012.

9.

Self-assembled peptide nanofibers raising durable antibody responses against a malaria epitope.

Rudra JS, Mishra S, Chong AS, Mitchell RA, Nardin EH, Nussenzweig V, Collier JH.

Biomaterials. 2012 Sep;33(27):6476-84. doi: 10.1016/j.biomaterials.2012.05.041. Epub 2012 Jun 12.

10.

Single nucleotide polymorphisms of pattern recognition receptors and chronic periodontitis.

Sahingur SE, Xia XJ, Gunsolley J, Schenkein HA, Genco RJ, De Nardin E.

J Periodontal Res. 2011 Apr;46(2):184-92. doi: 10.1111/j.1600-0765.2010.01327.x. Epub 2010 Dec 1.

PMID:
21118416
11.

The past decade in malaria synthetic peptide vaccine clinical trials.

Nardin E.

Hum Vaccin. 2010 Jan;6(1):27-38. Epub 2010 Jan 23. Review.

PMID:
20173408
13.

Genetic polymorphisms and immune responses.

De Nardin E.

Immunol Invest. 2009;38(3-4):198-202. Review. No abstract available.

PMID:
19811431
14.

Enhanced immunogenicity of Plasmodium falciparum peptide vaccines using a topical adjuvant containing a potent synthetic Toll-like receptor 7 agonist, imiquimod.

Othoro C, Johnston D, Lee R, Soverow J, Bystryn JC, Nardin E.

Infect Immun. 2009 Feb;77(2):739-48. doi: 10.1128/IAI.00974-08. Epub 2008 Dec 1.

15.

Imaging effector functions of human cytotoxic CD4+ T cells specific for Plasmodium falciparum circumsporozoite protein.

Frevert U, Moreno A, Calvo-Calle JM, Klotz C, Nardin E.

Int J Parasitol. 2009 Jan;39(1):119-32. doi: 10.1016/j.ijpara.2008.06.014. Epub 2008 Aug 6.

16.

Cellular effector mechanisms against Plasmodium liver stages.

Frevert U, Nardin E.

Cell Microbiol. 2008 Oct;10(10):1956-67. doi: 10.1111/j.1462-5822.2008.01211.x. Epub 2008 Jul 18. Review.

PMID:
18647171
17.

Phase I trial of an alhydrogel adjuvanted hepatitis B core virus-like particle containing epitopes of Plasmodium falciparum circumsporozoite protein.

Gregson AL, Oliveira G, Othoro C, Calvo-Calle JM, Thorton GB, Nardin E, Edelman R.

PLoS One. 2008 Feb 6;3(2):e1556. doi: 10.1371/journal.pone.0001556.

18.

Class II-restricted protective immunity induced by malaria sporozoites.

Oliveira GA, Kumar KA, Calvo-Calle JM, Othoro C, Altszuler D, Nussenzweig V, Nardin EH.

Infect Immun. 2008 Mar;76(3):1200-6. Epub 2007 Dec 26.

19.

A linear peptide containing minimal T- and B-cell epitopes of Plasmodium falciparum circumsporozoite protein elicits protection against transgenic sporozoite challenge.

Calvo-Calle JM, Oliveira GA, Watta CO, Soverow J, Parra-Lopez C, Nardin EH.

Infect Immun. 2006 Dec;74(12):6929-39. Epub 2006 Oct 9.

20.

Major histocompatibility complex and T cell interactions of a universal T cell epitope from Plasmodium falciparum circumsporozoite protein.

Parra-López C, Calvo-Calle JM, Cameron TO, Vargas LE, Salazar LM, Patarroyo ME, Nardin E, Stern LJ.

J Biol Chem. 2006 May 26;281(21):14907-17. Epub 2006 Mar 23.

21.

Fibrinogen-neutrophil interactions in response to fMLP and Porphyromonas gingivalis fimbrial peptides.

Sahingur SE, Boehm TK, Sojar HT, Sharma A, De Nardin E.

Immunol Invest. 2006;35(1):63-74.

PMID:
16531330
22.
23.

Effect of adjuvant on reactogenicity and long-term immunogenicity of the malaria Vaccine ICC-1132 in macaques.

Langermans JA, Schmidt A, Vervenne RA, Birkett AJ, Calvo-Calle JM, Hensmann M, Thornton GB, Dubovsky F, Weiler H, Nardin E, Thomas AW.

Vaccine. 2005 Sep 30;23(41):4935-43.

PMID:
15998554
24.

Safety and enhanced immunogenicity of a hepatitis B core particle Plasmodium falciparum malaria vaccine formulated in adjuvant Montanide ISA 720 in a phase I trial.

Oliveira GA, Wetzel K, Calvo-Calle JM, Nussenzweig R, Schmidt A, Birkett A, Dubovsky F, Tierney E, Gleiter CH, Boehmer G, Luty AJ, Ramharter M, Thornton GB, Kremsner PG, Nardin EH.

Infect Immun. 2005 Jun;73(6):3587-97.

25.

Arrest in the liver--a genetically defined malaria vaccine?

Frevert U, Nardin E.

N Engl J Med. 2005 Apr 14;352(15):1600-2. No abstract available.

PMID:
15829544
26.

Phase I testing of a malaria vaccine composed of hepatitis B virus core particles expressing Plasmodium falciparum circumsporozoite epitopes.

Nardin EH, Oliveira GA, Calvo-Calle JM, Wetzel K, Maier C, Birkett AJ, Sarpotdar P, Corado ML, Thornton GB, Schmidt A.

Infect Immun. 2004 Nov;72(11):6519-27.

27.

Quantitative Plasmodium sporozoite neutralization assay (TSNA).

Kumar KA, Oliveira GA, Edelman R, Nardin E, Nussenzweig V.

J Immunol Methods. 2004 Sep;292(1-2):157-64.

PMID:
15350520
28.

Association of Fcgamma receptor IIa genotype with chronic periodontitis in Caucasians.

Yamamoto K, Kobayashi T, Grossi S, Ho AW, Genco RJ, Yoshie H, De Nardin E.

J Periodontol. 2004 Apr;75(4):517-22.

PMID:
15152814
29.

Association of increased levels of fibrinogen and the -455G/A fibrinogen gene polymorphism with chronic periodontitis.

Sahingur SE, Sharma A, Genco RJ, De Nardin E.

J Periodontol. 2003 Mar;74(3):329-37.

PMID:
12710752
30.
31.

Immediate-type hypersensitivity and other clinical reactions in volunteers immunized with a synthetic multi-antigen peptide vaccine (PfCS-MAP1NYU) against Plasmodium falciparum sporozoites.

Edelman R, Wasserman SS, Kublin JG, Bodison SA, Nardin EH, Oliveira GA, Ansari S, Diggs CL, Kashala OL, Schmeckpeper BJ, Hamilton RG.

Vaccine. 2002 Dec 13;21(3-4):269-80. Erratum in: Vaccine. 2003 Jun 2;21(19-20):2689.

PMID:
12450702
32.
33.

Sporozoite antigens: biology and immunology of the circumsporozoite protein and thrombospondin-related anonymous protein.

Sinnis P, Nardin E.

Chem Immunol. 2002;80:70-96. Review. No abstract available.

PMID:
12058652
34.

Delayed-type hypersensitivity in volunteers immunized with a synthetic multi-antigen peptide vaccine (PfCS-MAP1NYU) against Plasmodium falciparum sporozoites.

Kublin JG, Lowitt MH, Hamilton RG, Oliveira GA, Nardin EH, Nussenzweig RS, Schmeckpeper BJ, Diggs CL, Bodison SA, Edelman R.

Vaccine. 2002 Mar 15;20(13-14):1853-61.

PMID:
11906775
35.
36.

Systemic inflammation in cardiovascular and periodontal disease: comparative study.

Glurich I, Grossi S, Albini B, Ho A, Shah R, Zeid M, Baumann H, Genco RJ, De Nardin E.

Clin Diagn Lab Immunol. 2002 Mar;9(2):425-32.

37.

Periodontal infections contribute to elevated systemic C-reactive protein level.

Noack B, Genco RJ, Trevisan M, Grossi S, Zambon JJ, De Nardin E.

J Periodontol. 2001 Sep;72(9):1221-7.

PMID:
11577954
38.
39.

Identification and characterization of human immunoglobulin G Fc receptors of Fusobacterium nucleatum.

Guo M, Han YW, Sharma A, De Nardin E.

Oral Microbiol Immunol. 2000 Apr;15(2):119-23.

PMID:
11155175
40.

A totally synthetic polyoxime malaria vaccine containing Plasmodium falciparum B cell and universal T cell epitopes elicits immune responses in volunteers of diverse HLA types.

Nardin EH, Calvo-Calle JM, Oliveira GA, Nussenzweig RS, Schneider M, Tiercy JM, Loutan L, Hochstrasser D, Rose K.

J Immunol. 2001 Jan 1;166(1):481-9.

42.

Synthetic malaria peptide vaccine elicits high levels of antibodies in vaccinees of defined HLA genotypes.

Nardin EH, Oliveira GA, Calvo-Calle JM, Castro ZR, Nussenzweig RS, Schmeckpeper B, Hall BF, Diggs C, Bodison S, Edelman R.

J Infect Dis. 2000 Nov;182(5):1486-96. Epub 2000 Oct 9.

PMID:
11023472
43.

Pyk2 and Syk participate in functional activation of granulocytic HL-60 cells in a different manner.

Miura Y, Tohyama Y, Hishita T, Lala A, De Nardin E, Yoshida Y, Yamamura H, Uchiyama T, Tohyama K.

Blood. 2000 Sep 1;96(5):1733-9.

44.

Chemotactic-like receptors and Abeta peptide induced responses in Alzheimer's disease.

Lorton D, Schaller J, Lala A, De Nardin E.

Neurobiol Aging. 2000 May-Jun;21(3):463-73.

PMID:
10858596
45.

Pre-erythrocytic malaria vaccine: mechanisms of protective immunity and human vaccine trials.

Nardin E, Zavala F, Nussenzweig V, Nussenzweig RS.

Parassitologia. 1999 Sep;41(1-3):397-402. Review.

PMID:
10697892
46.

Isolation and characterization of a human neutrophil aggregation defective mutant of Fusobacterium nucleatum.

Guo M, Reynolds H, Stinson M, De Nardin E.

FEMS Immunol Med Microbiol. 2000 Mar;27(3):241-6.

47.

Single nucleotide polymorphisms of the N-formyl peptide receptor in localized juvenile periodontitis.

Gwinn MR, Sharma A, De Nardin E.

J Periodontol. 1999 Oct;70(10):1194-201.

PMID:
10534074
48.

Preclinical evaluation of a synthetic Plasmodium falciparum MAP malaria vaccine in Aotus monkeys and mice.

Moreno CA, Rodriguez R, Oliveira GA, Ferreira V, Nussenzweig RS, Moya Castro ZR, Calvo-Calle JM, Nardin E.

Vaccine. 1999 Aug 20;18(1-2):89-99.

PMID:
10501239
49.

Human formyl peptide receptor function role of conserved and nonconserved charged residues.

Lala A, Gwinn M, De Nardin E.

Eur J Biochem. 1999 Sep;264(2):495-9.

50.

Immunogenicity of chimeric multiple antigen peptides based on Plasmodium falciparum antigens: impact of epitope orientation.

Ahlborg N, Nardin EH, Perlmann P, Berzins K, Andersson R.

Vaccine. 1998 Jan;16(1):38-44.

PMID:
9607007

Supplemental Content

Loading ...
Support Center